Stereotactic Body Radiotherapy Boost for Pelvic Nodes in Cervical Cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an observational comparison of two radiotherapy approaches for cervical cancer: a SBRT boost to involved pelvic nodes versus a conventional Simultaneous Integrated Boost to the pelvic nodes, in patients with stage IIIC disease. The study focuses on safety by tracking acute gastrointestinal and genitourinary toxicity greater than grade 3 within 30 days after completing treatment. Eligible participants have no prior pelvic radiation or surgery and an ECOG performance status of 0-2, while those with non-Stage IIIC disease, prior malignancies, uncontrolled comorbidities, or autoimmune conditions are excluded. The lead institution is AIIMS, Delhi, with collaboration across participating centers in India.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Patients with stage IIIC cervical cancer
2. No previous pelvic radiation therapy or surgery
3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2

Exclusion Criteria:

1. Patients with stage I or stage II or stage IV disease.
2. Patients with prior malignancies or active autoimmune diseases
3. Uncontrolled medical comorbidity

Where it's running

• All India Institute of Medical Sciences
  Delhi, National Capital Territory of Delhi, India Recruiting
• Karun Kamboj
  Delhi, National Capital Territory of Delhi, India Recruiting
• National Cancer Institute, All India Institute of Medical Sciences, New Delhi, India
  New Delhi, New Delhi, India Recruiting

Study contacts

• Study coordinator: Karun Kamboj, Md
• Email: karunkamboj04@aiims.edu
• Phone: 9416613389

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Combining chemotherapy with immunotherapy for older adults with advanced lung cancer

  This study is testing if adding chemotherapy to immunotherapy can help older adults with advanced lung cancer live longer and feel better compared to just using immunotherapy alone.

  Recruiting at 271 sites Phase 3 National Cancer Institute (NCI) · Fayetteville, Arkansas and 329 other locations · NCT06096844

• Combining SX-682 and Pembrolizumab for Advanced Lung Cancer Treatment

  This study is testing if a new oral medication called SX-682, when combined with the IV drug pembrolizumab, can help people with advanced lung cancer feel better and improve their treatment outcomes.

  Recruiting Phase 2 University of Washington · Seattle, Washington · NCT05570825

• Personalized vaccine combined with pembrolizumab for advanced solid tumors

  This study is testing a new personalized cancer vaccine combined with pembrolizumab to see if it helps people with advanced solid tumors fight their cancer better.

  Recruiting Phase 1/2 Mayo Clinic · Jacksonville, Florida · NCT05269381

• Using papaverine with chemoradiation to treat advanced non-small cell lung cancer

  This study is testing the best dose of papaverine combined with chemotherapy and radiation to see if it helps people with advanced non-small cell lung cancer live longer and control their tumors better.

  Recruiting at 2 sites Phase 1 Ohio State University Comprehensive Cancer Center · Duarte, California and 1 other locations · NCT05136846

• Assessing heart health in lung cancer patients receiving personalized chemoradiation

  This study is testing how personalized chemoradiation treatment for lung cancer affects heart health in patients and if adjusting the treatment can help reduce heart disease risk.

  Recruiting M.D. Anderson Cancer Center · Houston, Texas · NCT05010109

• Combining local therapy and durvalumab for advanced lung cancer after initial treatment

  This study is testing whether combining local treatments like surgery or radiation with the immunotherapy durvalumab can help people with advanced lung cancer live longer and feel better after their initial treatment.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT04892953

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.